Details of the Drug

General Information of Drug (ID: DMPQAGE)

Drug Name
Mycophenolate mofetil
Synonyms
mycophenolate mofetil; 128794-94-5; CellCept; 115007-34-6; RS 61443; RS-61443; Munoloc; Mycophenolic acid morpholinoethyl ester; TM-MMF; Mycophenylate mofetil; Mycophenolatemofetil; UNII-9242ECW6R0; HSDB 7436; Cellcept (TN); 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; CHEBI:8764; C23H31NO7; Mycophenolate mofetil (CellCept); 9242ECW6R0; 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate; Myfenax; RS-61443-190; CellCept; MMF; CellCept (TN); ME-MPA; MMF CellCept(TM); R-99; Mycophenolate mofetil (JAN/USAN); CellCept, RS 61443, TM-MMF, Mycophenolate mofetil; 2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate; 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate;4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
Indication
Disease Entry ICD 11 Status REF
Hepatosplenic T-cell lymphoma N.A. Approved [1]
Interstitial cystitis GC00.3 Approved [1]
Large granular lymphocytic leukemia 2A90.1 Approved [1]
Lupus nephritis 4A40.0Y Approved [1]
MALT lymphoma N.A. Approved [1]
Myeloid leukaemia 2B33.1 Approved [1]
Myeloproliferative neoplasm 2A20 Approved [1]
Nodal marginal zone lymphoma 2A85.0 Approved [1]
Organ transplant rejection NE84 Approved [2]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [1]
Recurrent adult burkitt lymphoma 2A85.6 Approved [1]
Small intestine lymphoma N.A. Approved [1]
Splenic marginal zone lymphoma N.A. Approved [1]
Systemic lupus erythematosus 4A40.0 Approved [1]
Testicular lymphoma N.A. Approved [1]
Pemphigus vulgaris EB40 Phase 3 [2]
Classic Hodgkin lymphoma N.A. Investigative [1]
Immune System disease 4A01-4B41 Investigative [3]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [4]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Immunosuppressive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 433.5
Logarithm of the Partition Coefficient (xlogp) 3.2
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Elimination
0% of drug is excreted from urine in the unchanged form [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 47.4536 micromolar/kg/day [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.043 mg/mL [5]
Chemical Identifiers
Formula
C23H31NO7
IUPAC Name
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
Canonical SMILES
CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\\C)/CCC(=O)OCCN3CCOCC3)O
InChI
InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+
InChIKey
RTGDFNSFWBGLEC-SYZQJQIISA-N
Cross-matching ID
PubChem CID
5281078
ChEBI ID
CHEBI:8764
CAS Number
128794-94-5
DrugBank ID
DB00688
TTD ID
D04FBR
VARIDT ID
DR00243
INTEDE ID
DR1118
ACDINA ID
D00449
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) TTTB4UP IMDH2_HUMAN Inhibitor [7]
Prostaglandin E2 receptor EP2 (PTGER2) TT1ZAVI PE2R2_HUMAN Modulator [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [8]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [9]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [8]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [11]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [10]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [10]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [10]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [12]
UDP-glucuronosyltransferase 1A10 (UGT1A10) DEL5N6Y UD110_HUMAN Substrate [13]
UDP-glucuronosyltransferase 1A6 (UGT1A6) DESD26P UD16_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hepatosplenic T-cell lymphoma
ICD Disease Classification
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin E2 receptor EP2 (PTGER2) DTT PTGER2 2.77E-06 1.15 1.37
P-glycoprotein 1 (ABCB1) DTP P-GP 9.96E-01 9.10E-02 1.78E-01
Breast cancer resistance protein (ABCG2) DTP BCRP 3.20E-01 -2.44E-01 -2.70E-01
Multidrug resistance-associated protein 2 (ABCC2) DTP MRP2 6.57E-01 -7.03E-03 -3.29E-02
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 7.75E-01 3.79E-03 1.43E-02
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 5.94E-01 -5.43E-03 -2.82E-02
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.98E-01 1.01E-01 3.33E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 7.97E-02 -4.55E-02 -3.54E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 3.74E-03 -6.47E-02 -1.18E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.50E-01 8.27E-02 3.14E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Mycophenolate mofetil
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Mycophenolate mofetil and Azathioprine. Transplant rejection [NE84] [14]
Coadministration of a Drug Treating the Disease Different from Mycophenolate mofetil (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Mycophenolate mofetil due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [15]
Clindamycin DM15HL8 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Clindamycin. Acne vulgaris [ED80] [14]
Cefuroxime DMSIMD8 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefuroxime. Acute bronchitis [CA42] [14]
Framycetin DMF8DNE Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Framycetin. Alcoholic liver disease [DB94] [14]
Paromomycin DM1AGXN Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Paromomycin. Amoebiasis [1A36] [14]
Metronidazole DMTIVEN Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Metronidazole. Amoebiasis [1A36] [14]
Cefamandole DMNEXZF Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefamandole. Anaerobic bacterial infection [1A00-1A09] [14]
Aminophylline DML2NIB Minor Increased plasma concentration of Mycophenolate mofetil and Aminophylline due to competitive binding of plasma proteins. Asthma [CA23] [14]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Roflumilast. Asthma [CA23] [16]
Cefotetan DM07TX3 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefotetan. Bacterial infection [1A00-1C4Z] [14]
Ofloxacin DM0VQN3 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [14]
Kanamycin DM2DMPO Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Kanamycin. Bacterial infection [1A00-1C4Z] [14]
Tindamax DM3OWT4 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Tindamax. Bacterial infection [1A00-1C4Z] [14]
Ceftizoxime DM3VOGS Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Ceftizoxime. Bacterial infection [1A00-1C4Z] [14]
Dalfopristin DM4LTKV Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Dalfopristin. Bacterial infection [1A00-1C4Z] [14]
Clarithromycin DM4M1SG Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Clarithromycin. Bacterial infection [1A00-1C4Z] [14]
Ticarcillin DM4ME02 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Ticarcillin. Bacterial infection [1A00-1C4Z] [14]
Cefoperazone DM53PV8 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefoperazone. Bacterial infection [1A00-1C4Z] [14]
Meropenem DM62UHC Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Meropenem. Bacterial infection [1A00-1C4Z] [14]
Cefprozil DM7DSYP Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefprozil. Bacterial infection [1A00-1C4Z] [14]
Sulfamethoxazole DMB08GE Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [14]
Sparfloxacin DMB4HCT Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [14]
Ceftriaxone DMCEW64 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Ceftriaxone. Bacterial infection [1A00-1C4Z] [14]
Streptomycin DME1LQN Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Streptomycin. Bacterial infection [1A00-1C4Z] [14]
Dalbavancin DMGMNH3 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Dalbavancin. Bacterial infection [1A00-1C4Z] [14]
Gemifloxacin DMHT34O Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [14]
Cefepime DMHVWIK Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefepime. Bacterial infection [1A00-1C4Z] [14]
Imipenem DMI9FBP Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Imipenem. Bacterial infection [1A00-1C4Z] [14]
Meticillin DMIKHN0 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Meticillin. Bacterial infection [1A00-1C4Z] [14]
Norfloxacin DMIZ6W2 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [14]
ABT-492 DMJFD2I Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by ABT-492. Bacterial infection [1A00-1C4Z] [14]
Cefpodoxime DMJUNY5 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefpodoxime. Bacterial infection [1A00-1C4Z] [14]
Cefaclor DMJXDGC Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefaclor. Bacterial infection [1A00-1C4Z] [14]
Gentamicin DMKINJO Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Gentamicin. Bacterial infection [1A00-1C4Z] [14]
Cefadroxil DMMC345 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefadroxil. Bacterial infection [1A00-1C4Z] [14]
Rabeprazole DMMZXIW Moderate Decreased absorption of Mycophenolate mofetil due to altered gastric pH caused by Rabeprazole. Bacterial infection [1A00-1C4Z] [14]
Bacampicillin DMP54C7 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Bacampicillin. Bacterial infection [1A00-1C4Z] [14]
Cefazolin DMPDYFR Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefazolin. Bacterial infection [1A00-1C4Z] [14]
Netilmicin DMRD1QK Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Netilmicin. Bacterial infection [1A00-1C4Z] [14]
Novobiocin DMRFWGK Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Novobiocin. Bacterial infection [1A00-1C4Z] [14]
Levofloxacin DMS60RB Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [14]
Cefditoren DMSUVM1 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefditoren. Bacterial infection [1A00-1C4Z] [14]
Oxacillin DMTAFY4 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Oxacillin. Bacterial infection [1A00-1C4Z] [14]
Cefonicid DMTX2BH Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefonicid. Bacterial infection [1A00-1C4Z] [14]
Cefradine DMUNSWV Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefradine. Bacterial infection [1A00-1C4Z] [14]
Cloxacillin DMUTL7O Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cloxacillin. Bacterial infection [1A00-1C4Z] [14]
Amoxicillin DMUYNEI Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Amoxicillin. Bacterial infection [1A00-1C4Z] [14]
Troleandomycin DMUZNIG Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Troleandomycin. Bacterial infection [1A00-1C4Z] [14]
Minocycline DMVN5OH Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Minocycline. Bacterial infection [1A00-1C4Z] [14]
Lomefloxacin DMVRH9C Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [14]
Cefoxitin DMY8NC4 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefoxitin. Bacterial infection [1A00-1C4Z] [14]
Tetracycline DMZA017 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Tetracycline. Bacterial infection [1A00-1C4Z] [14]
Ceftibuten DMWV2AG Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Ceftibuten. Bronchitis [CA20] [14]
Oxtriphylline DMLHSE3 Minor Increased plasma concentration of Mycophenolate mofetil and Oxtriphylline due to competitive binding of plasma proteins. Cough [MD12] [14]
SODIUM CITRATE DMHPD2Y Moderate Decreased absorption of Mycophenolate mofetil due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [15]
Benzylpenicillin DMS9503 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Benzylpenicillin. Discovery agent [N.A.] [14]
Fosphenytoin DMOX3LB Minor Increased plasma concentration of Mycophenolate mofetil and Fosphenytoin due to competitive binding of plasma proteins. Epilepsy/seizure [8A61-8A6Z] [14]
Ethotoin DMXWOCP Minor Increased plasma concentration of Mycophenolate mofetil and Ethotoin due to competitive binding of plasma proteins. Epilepsy/seizure [8A61-8A6Z] [14]
Lincomycin DMVTHER Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Lincomycin. Gram-positive bacterial infection [1B74-1F40] [14]
Rifampin DMA8J1G Major Decreased clearance of Mycophenolate mofetil and Rifampin due to competitive inhibition of the same transporter. HIV-infected patients with tuberculosis [1B10-1B14] [16]
Didanosine DMI2QPE Moderate Decreased absorption of Mycophenolate mofetil due to altered gastric pH caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [15]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Mycophenolate mofetil and Teriflunomide. Hyper-lipoproteinaemia [5C80] [17]
Quinapril DMR8H31 Moderate Decreased absorption of Mycophenolate mofetil due to formation of complexes caused by Quinapril. Hypertension [BA00-BA04] [16]
TP-434 DM5A31S Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by TP-434. Infectious gastroenteritis/colitis [1A40] [14]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Mycophenolate mofetil and Denosumab. Low bone mass disorder [FB83] [18]
Sulphadoxine DMZI2UF Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Sulphadoxine. Malaria [1F40-1F45] [14]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Mycophenolate mofetil due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [19]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Tecfidera. Multiple sclerosis [8A40] [20]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Siponimod. Multiple sclerosis [8A40] [21]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Fingolimod. Multiple sclerosis [8A40] [22]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Ocrelizumab. Multiple sclerosis [8A40] [23]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Ozanimod. Multiple sclerosis [8A40] [16]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [24]
Esomeprazole DM7BN0X Moderate Decreased absorption of Mycophenolate mofetil due to altered gastric pH caused by Esomeprazole. Peptic ulcer [DA61] [14]
Gatifloxacin DMSL679 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [14]
Colistimethate DMZ9BMU Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Colistimethate. Respiratory infection [CA07-CA4Z] [14]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Rilonacept. Rheumatoid arthritis [FA20] [25]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Golimumab. Rheumatoid arthritis [FA20] [26]
Sulfasalazine DMICA9H Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Sulfasalazine. Rheumatoid arthritis [FA20] [14]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Leflunomide. Rheumatoid arthritis [FA20] [17]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Mycophenolate mofetil when combined with Anthrax vaccine. Sepsis [1G40-1G41] [27]
Cephapirin DMV2JNY Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cephapirin. Sepsis [1G40-1G41] [14]
Tedizolid DMG2SKR Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Tedizolid. Skin and skin-structure infection [1F28-1G0Z] [14]
Pitolisant DM8RFNJ Moderate Accelerated clearance of Mycophenolate mofetil due to the transporter induction by Pitolisant. Somnolence [MG42] [16]
Cinoxacin DM4EWNS Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cinoxacin. Urinary tract infection [GC08] [14]
Nitrofurantoin DM7PQIK Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Nitrofurantoin. Urinary tract infection [GC08] [14]
Doripenem DM9UCJK Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Doripenem. Urinary tract infection [GC08] [14]
Plazomicin DMKMBES Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Plazomicin. Urinary tract infection [GC08] [14]
Nalidixic acid DMRM0JV Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Nalidixic acid. Urinary tract infection [GC08] [14]
Mezlocillin DMY5JEP Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Mezlocillin. Urinary tract infection [GC08] [14]
Secnidazole DMJ18YL Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Secnidazole. Vaginal discharge [MF3A] [14]
⏷ Show the Full List of 91 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
⏷ Show the Full List of 29 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Mycophenolate mofetil 250 mg capsule 250 mg Oral Capsule Oral
Mycophenolate mofetil 500 mg tablet 500 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Mycophenolate mofetil FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6831).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
4 High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses. J Virol. 2019 May 29;93(12). pii: e00023-19.
5 BDDCS applied to over 900 drugs
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Clinical pipeline report, company report or official report of Roche (2009).
8 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
9 Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64.
10 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
11 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
12 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
13 [Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7.
14 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
15 Bullingham R, Shah J, Goldblum R, Schiff M "Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients." Br J Clin Pharmacol 41 (1996): 513-6. [PMID: 8799515]
16 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
18 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
19 Canadian Pharmacists Association.
20 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
21 Cerner Multum, Inc. "Australian Product Information.".
22 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
23 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
24 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
25 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
26 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
27 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]